Descriptive epidemiology of ovarian cancer in the United States, 1992-1997

Goodman, MT; Howe, Holly L.

doi:10.1002/cncr.11339

Cited by 54 publications

(27 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We found that PFTCs were most often unilateral and diagnosed slightly more often at a localized stage than at regional or distant stages. This is in contrast to ovarian cancer, where over 50% of malignant tumors are diagnosed at a distant stage [30]. The difference between PFTC and ovarian cancer in stage at diagnosis may be primarily due to the fact that signs and symptoms such as abnormal vaginal bleeding or discharge and abdominal pain together with an abdominal mass are largely present for women with PFTC, while this is not the case for many women with ovarian cancer, allowing for an earlier stage at diagnosis for PFTC [27].…”

Section: Discussionmentioning

confidence: 88%

The incidence of primary fallopian tube cancer in the United States

Stewart

Wike²,

Foster

et al. 2007

Gynecologic Oncology

102

View full text Add to dashboard Cite

Objective. The objective of this study was to report the incidence of primary fallopian tube carcinoma (PFTC) in the United States population and to describe associated demographic and clinical factors.Methods. A total of 3051 PFTC cases diagnosed from 1998 to 2003, reported from population-based cancer registries, were analyzed. Registries contributing data represent 83.1% of the U.S. population. Data are presented by age, race/ethnicity, U.S. census region, stage, histology, grade, and laterality. Trends in incidence over time from 1998 to 2003 are also presented.Results. The incidence rate was 0.41 per 100,000 women from 1998 to 2003. White, non-Hispanic women and women aged 60-79 had the highest incidence rates ( p b 0.0001). The majority (88%) of PFTCs were adenocarcinomas; serous adenocarcinomas accounted for 44% and endometrioid adenocarcinomas for 19% of adenocarcinoma diagnoses. Essentially half (49.9%) of PFTCs were poorly differentiated; 89% were unilateral at diagnosis. Stage at diagnosis was fairly evenly distributed among localized (36%), regional (30%), and distant (32%). Overall, rates of PFTC remained stable over time. Among women aged 65-69, incidence rates increased significantly by 3.8% per year from 1998 to 2003 ( p b 0.05).Conclusions. This report provides characteristics of PFTC using the largest number of cases assembled in one study to date. Although the demographic characteristics of PFTC are similar to those of ovarian cancer, stage at diagnosis and the stable trend observed in PFTC are in contrast to ovarian cancer. Future studies should focus on examining the increasing trend of PFTC among 65-to 69-year-old women. Published by Elsevier Inc.

show abstract

Section: Discussionmentioning

confidence: 88%

The incidence of primary fallopian tube cancer in the United States

Stewart

Wike²,

Foster

et al. 2007

Gynecologic Oncology

102

View full text Add to dashboard Cite

show abstract

“…Thus, the role of decreased SELENBP1 in ovarian cancer prognosis is not clear. Ovarian cancer remains the most lethal gynecologic malignancy for women and it represents 2.5% total cancer deaths in the United States [23][24][25][26]. Identifying altered SELENBP1 expression may be significant for the treatment of ovarian cancer since selenium has been shown to have an important role in the reduction and prevention of other cancers.…”

Section: Introductionmentioning

confidence: 99%

Selenium-Binding Protein 1 expression in ovaries and ovarian tumors in the laying hen, a spontaneous model of human ovarian cancer

Stammer

Edassery

Barua

et al. 2008

Gynecologic Oncology

View full text Add to dashboard Cite

Objective-Reduced Selenium-Binding Protein 1 (SELENBP1) expression was recently shown in multiple cancers. There is little information on the expression and function of SELENBP1 in cancer progression. In order to develop a better understanding of the role of SELENBP1 in ovarian cancer, our objective was to determine if SELENBP1 is expressed in the normal ovaries and ovarian tumors in the egg-laying hen, a spontaneous model of human ovarian cancer.Methods-SPB1 mRNA expression in normal ovary (n=20) and ovarian tumors (n=23) was evaluated by RT-PCR. Relative levels of mRNA were compared by quantitative RT-PCR (qRT-PCR) in selected samples. SELENBP1 protein expression was evaluated by 1D Western Blot and immunohistochemistry with a commercial anti-human SELENBP1 antibody.Results-SELENBP1 mRNA and protein was expressed in 100% of normal and ovarian tumors and qRT-PCR confirmed decreased mRNA expression in 80% of ovarian tumors. SELENBP1 was primarily localized in surface epithelial cells of normal ovaries. In ovaries containing early tumor lesions, SELENBP1 expression was reduced in the surface epithelium near the tumor and was expressed in tumor cells, while more distant regions with normal histology retained SELENBP1 expression in the surface epithelium.Conclusions-We have shown for the first time that SELENBP1 is expressed in both normal ovaries and ovarian tumors in the hen and that SELENBP1 expression is altered in the vicinity of the tumor. Furthermore, SELENBP1 expression in normal ovarian surface epithelium and in ovarian tumors parallels that previously reported for ovarian cancer in women.

show abstract

“…The lack of symptoms in early-stage disease often means that the disease is diagnosed at a late stage, resulting in poor overall 5-year survival. 1,2 Most ovarian tumours are categorised as either epithelial, germ cell or sex cord tumours. Epithelial tumours, which are thought to arise from the ovarian surface epithelium (OSE), account for approximately 60% of all ovarian tumours and 90% of malignant ovarian cancers.…”

mentioning

confidence: 99%

A modified medium that significantly improves the growth of human normal ovarian surface epithelial (OSE) cells in vitro

Wilbanks

Balkwill

et al. 2004

Laboratory Investigation

View full text Add to dashboard Cite

Approximately 90% of malignant ovarian tumours are epithelial and thought to arise from a single cell layer, the ovarian surface epithelium. In culture, human normal ovarian surface epithelial (OSE) cells have a very limited lifespan before they senesce, rarely progressing beyond 10 population doublings. This has restricted the use of normal OSE cells for studying the biology of ovarian surface epithelium and identifying molecular events that contribute to malignant transformation. We have investigated the conditions for culturing human, normal OSE cells in vitro using modified media. Culturing normal OSE cells in a modified medium (NOSE-CM) supplemented with epidermal growth factor, hydrocortisone, insulin and bovine pituitary extract led to significant improvements in the seeding and cloning efficiencies, overall cell growth and lifespan compared to culturing in a basic, nonsupplemented medium (BM) and previously used media (F-12 K medium and William's medium E). Cells cultured in NOSE-CM underwent, on an average, 19.0 population doublings (95% CI 16.3-21.7); cells cultured in BM underwent 0.43-3.52 population doublings over a similar time period. Growth curves established for different lines indicated that OSE cells continued to grow beyond passage 11 and up to passage 18 in NOSE-CM, but never beyond passage 7 when cultured in BM. It is likely that establishing optimal conditions for the growth of OSE cells in vitro will enable studies of the biological and genetic mechanisms of transformation in epithelial ovarian cancers.

show abstract

Descriptive epidemiology of ovarian cancer in the United States, 1992-1997

Cited by 54 publications

References 53 publications

The incidence of primary fallopian tube cancer in the United States

The incidence of primary fallopian tube cancer in the United States

Selenium-Binding Protein 1 expression in ovaries and ovarian tumors in the laying hen, a spontaneous model of human ovarian cancer

A modified medium that significantly improves the growth of human normal ovarian surface epithelial (OSE) cells in vitro

Contact Info

Product

Resources

About